Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Reata Pharma 5320 LEGACY DRIVE PLANO TX 75024 USA

www.reatapharma.com P: 972-865-2219

Description:

Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates - bardoxolone methyl (bardoxolone) and omaveloxolone for rare forms of chronic kidney disease (CKD) and neurological diseases, respectively.

Key Statistics

Overview:

Market Capitalization, $K 6,575,535
Enterprise Value, $K 6,533,225
Shares Outstanding, K 38,150
Annual Sales, $ 2,220 K
Annual Net Income, $ -311,900 K
Last Quarter Sales, $ 22,750 K
Last Quarter Net Income, $ 193,000 K
EBIT, $ -351,550 K
EBITDA, $ -353,730 K
60-Month Beta 1.42
% of Insider Shareholders 26.80%
Float, K 27,926
% Float 73.20%
Short Volume Ratio 0.14

Growth:

1-Year Return 679.20%
3-Year Return 68.93%
5-Year Return 152.54%
5-Year Revenue Growth -95.38%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.32 on 08/08/23
Next Earnings Date 11/14/23
Earnings Per Share ttm -7.62
EPS Growth vs. Prev Qtr 26.11%
EPS Growth vs. Prev Year -14.85%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RETA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -73.39%
Profit Margin % -14,049.55%
Debt/Equity 0.84
Price/Sales 2,966.61
Price/Cash Flow N/A
Price/Book 74.73
Book Value/Share 2.31
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar